Oral candidiasis in HIV+ patients under treatment with protease inhibitors

Braz Oral Res. 2008 Oct-Dec;22(4):371-7. doi: 10.1590/s1806-83242008000400015.

Abstract

The purpose of this work was to evaluate the influence of Protease Inhibitors (PI) on the occurrence of oral candidiasis in 111 HIV+ patients under PI therapy (Group A). The controls consisted of 56 patients that were not using PI drugs (Group B) and 26 patients that were not using any drugs for HIV therapy (Group C). The patient's cd4 cell counts were taken in account for the correlations. One hundred and ninety three patients were evaluated. The PI did not affect the prevalence of oral candidiasis (p = 0.158) or the frequency of C. albicans isolates (p = 0.133). Patients with lower cd4 cell counts showed a higher frequency of C. albicans isolates (p = 0.046) and a greater occurrence of oral candidiasis (p = 0.036).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / epidemiology
  • AIDS-Related Opportunistic Infections / microbiology
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Adolescent
  • Adult
  • Aged
  • Analysis of Variance
  • Antiviral Agents / therapeutic use*
  • Brazil / epidemiology
  • CD4 Lymphocyte Count
  • Candida albicans / drug effects
  • Candida albicans / isolation & purification*
  • Candidiasis, Oral / drug therapy
  • Candidiasis, Oral / epidemiology
  • Candidiasis, Oral / microbiology*
  • Chi-Square Distribution
  • Female
  • HIV Protease Inhibitors / pharmacology
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Mouth Mucosa / microbiology*
  • Treatment Outcome
  • Viral Load
  • Young Adult

Substances

  • Antiviral Agents
  • HIV Protease Inhibitors